- Home
- MKZR vs PHIO Comparison
MKZR vs PHIO Comparison
Compare MKZR & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- PHIO
- Stock Information
- Founded
- MKZR 2012
- PHIO 2011
- Country
- MKZR United States
- PHIO United States
- Employees
- MKZR N/A
- PHIO N/A
- Industry
- MKZR
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- PHIO Health Care
- Exchange
- MKZR Nasdaq
- PHIO Nasdaq
- Market Cap
- MKZR 10.3M
- PHIO 12.1M
- IPO Year
- MKZR N/A
- PHIO N/A
- Fundamental
- Price
- MKZR $4.92
- PHIO $1.47
- Analyst Decision
- MKZR
- PHIO Strong Buy
- Analyst Count
- MKZR 0
- PHIO 3
- Target Price
- MKZR N/A
- PHIO $10.67
- AVG Volume (30 Days)
- MKZR 42.8K
- PHIO 8.4M
- Earning Date
- MKZR 11-18-2025
- PHIO 11-11-2025
- Dividend Yield
- MKZR 20.49%
- PHIO N/A
- EPS Growth
- MKZR N/A
- PHIO N/A
- EPS
- MKZR N/A
- PHIO N/A
- Revenue
- MKZR $21,294,932.00
- PHIO N/A
- Revenue This Year
- MKZR N/A
- PHIO N/A
- Revenue Next Year
- MKZR N/A
- PHIO N/A
- P/E Ratio
- MKZR N/A
- PHIO N/A
- Revenue Growth
- MKZR 21.25
- PHIO N/A
- 52 Week Low
- MKZR $3.89
- PHIO $0.97
- 52 Week High
- MKZR $55.00
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- MKZR 44.65
- PHIO 19.20
- Support Level
- MKZR $4.80
- PHIO $2.08
- Resistance Level
- MKZR $5.60
- PHIO $4.19
- Average True Range (ATR)
- MKZR 0.46
- PHIO 0.27
- MACD
- MKZR -0.02
- PHIO -0.07
- Stochastic Oscillator
- MKZR 22.45
- PHIO 1.09
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.